

ASX ANNOUNCEMENT

BENITEC INVESTOR PRESENTATION

Sydney, 5 August 2014: Benitec Biopharma Limited (ASX: BLT) (OTC: BTEBY) is pleased to release a copy of the presentation that Dr David Suhy, Senior VP Research & Development, will be delivering to investors during a non-deal roadshow in Melbourne and Sydney.

The presentation highlights Benitec's progress on the company's ddRNAi programs and provides an update on Phase I/IIa Hepatitis C trials.

For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.

Company	Investor relations
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com	Jane Lowe Buchan Consulting Tel: +61 (2) 9237 2807 Email: jlowe@buchanwe.com.au

About Benitec Biopharma Limited:

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX: BLT, OTC: BTEBY) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.